CDK9-IN-40 is an orally active inhibitor of CDK9, with an IC50 of 5.5 nM. It shows reduced activity against CDK1, CDK2, CDK4, and CDK6. CDK9-IN-40 can arrest the cell cycle, induce apoptosis (cell death), and inhibit tumor growth, demonstrating potent anticancer activity.
Target:
Apoptosis|||CDK
* VAT and and shipping costs not included. Errors and price changes excepted
